On October 6, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported that Dara Burdette, Ph.D., Senior Director of Discovery Research at Tempest, will present on the company’s TREX1 pipeline asset and will serve as chairperson for the "New Approaches to Solid Tumor Targeting" session at the Emerging Technologies for IO Targeting and Discovery Summit taking place October 13-14, 2022 in Boston, MA (Press release, Tempest Therapeutics, OCT 6, 2022, View Source [SID1234621765]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TREX1 Presentation

Dr. Burdette’s presentation will describe the company’s approach to identify and characterize novel small molecule inhibitors of the 3’-5’ DNA repair exonuclease, TREX1. TREX1 inhibits cGAS/STING signaling and is induced in tumor cells due to genetic instability or therapeutic intervention. Tempest’s program aims to generate an anti-tumor response through selectively activating the STING pathway in advanced metastatic cancers with orally available small molecule inhibitors of TREX1.

Presentation details:

In addition, Nicholas DeVito, M.D., a medical oncologist and medical instructor in the laboratory of Dr. Brent Hanks, M.D., Ph.D. at Duke University School of Medicine, will be giving a presentation describing pre-clinical results with TPST-1495, Tempest’s clinical-stage dual inhibitor of the EP2 and EP4 prostaglandin E2 receptors, in mice bearing tumors with designated gene expression profiles.

On October 6, 2022 Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, reported two poster presentations at the 2022 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Meeting in Boston, MA, from November 10-12, 2022 (Press release, Imvax, OCT 6, 2022, View Source [SID1234621762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, Imvax will present data providing new insights into the mechanism of action of the company’s most advanced product candidate, IGV-001, for the treatment of glioblastoma. The company also will share in vivo data supporting the antitumor activity of Imvax’s tumor-derived immunotherapy platform for ovarian, liver and bladder cancers.

On October 6, 2022 Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported it has successfully imaged its first participant in the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative prostate cancer (Press release, Clarity Pharmaceuticals, OCT 6, 2022, View Source [SID1234621758]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SABRE (Copper-64 SAR-BisPSMA in Biochemical Recurrence of prostate cancer) is a Phase II Positron Emission Tomography (PET) imaging trial of participants with PSMA-negative biochemical recurrence (BCR) of prostate cancer following definitive therapy. It is a multi-centre, single arm, non-randomised, open-label trial of 64Cu-labelled SAR-Bombesin in 50 participants. The primary objectives of the trial are to investigate the safety and tolerability of the product as well as its ability to correctly detect recurrence of prostate cancer.

Dr Luke Nordquist, CEO, Urologic Medical Oncologist and Principal Investigator at the Urology Cancer Center and GU Research Network in Omaha, Nebraska, commented, "We are very excited to have recruited and imaged the first participant in this trial which will explore the clinical benefits of the novel SAR-Bombesin agent. Based on the promising preclinical and clinical data to date, SAR-Bombesin shows great potential for improving the diagnosis and treatment for not only patients with prostate cancer that are PSMA negative, but also across broader prostate cancer indications.

"SABRE is the third trial with Clarity’s Targeted Copper Theranostics (TCTs) that GURN is recruiting into. This momentum is underpinned by our belief that the TCTs are the next-generation products that will enable the radiopharmaceutical field to overcome the manufacturing and supply chain challenges associated with the current products in the market and facilitate the expansion of radiopharmaceuticals into the large global oncology market. We look forward to generating data from the trial to validate the potential clinical benefits for large patient populations and improve patient care."

Clarity’s Executive Chairman, Dr Alan Taylor, commented, "We are very excited to progress the SABRE trial in the United States as we are already seeing an improved treatment paradigm in the management of PSMA-negative disease for patients with SAR-Bombesin who were imaged under the Therapeutic Goods Agency’s Special Access Scheme in Australia2.

"Given the data to date indicates the potential diagnostic and therapeutic benefits of SAR-Bombesin, we look forward to generating further evidence as we accelerate the product to market. Subject to the outcome of the SABRE trial, Clarity is planning to launch a pivotal Phase III diagnostic trial for first product approvals in the US. We are also preparing to run a theranostic trial with an Investigational New Drug (IND) application scheduled for submission to the US Food and Drug Administration (FDA) later this year. We look forward to progressing our SAR-Bombesin program and potentially providing a large patient population with accurate and precise detection and treatment of their prostate cancer," said Dr Taylor.

Clarity’s Prostate Cancer clinical trial program overview

About SAR-Bombesin
SAR-Bombesin is a highly targeted pan-cancer radiopharmaceutical with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr) present on cells of a range of cancers, including but not limited to prostate, breast and ovarian cancers. GRPr is found in approximately 75-100% of prostate cancers, including prostate cancers that don’t express PSMA (PSMA-negative)3-7. The product utilises Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

About Prostate Cancer
Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death worldwide8. The National Cancer Institute estimates in 2022 there will be 268,490 new cases of prostate cancer in the US and around 34,500 deaths from the disease9.

Approximately 20% of prostate cancers with BCR are PSMA-PET negative10-13. These patients are therefore unlikely to respond to therapeutic PSMA-targeted products and currently have few treatment options available to them. Given the prostate cancer indication is one of the largest in oncology, there is a significant unmet medical need in this segment.

On October 5, 2022 Biohaven reported the company officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3 (Press release, Biohaven Pharmaceutical, OCT 5, 2022, View Source [SID1234643836]). Led by the same CEO, Vlad Coric, and publicly traded under the same stock ticker, the new Biohaven retains a pipeline of experimental medicines for a range of neurological disorders, four of which are already in clinical testing. It holds nearly $258 million in cash to fund its operations and no debt.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am enthusiastic about continuing to lead our team in new, exciting directions as we strive to bring best-in-class therapies to patients for a broad range of diseases with few or no treatment options," said Coric in an Oct. 4 statement. "If past is prologue, this proven team will continue to succeed in achieving its mission for patients, shareholders and employees."

So far, investors appear to be giving Coric and his team some credit. Biohaven’s shares, which opened trading on Tuesday at a reset value of $7.30 per share, rose to more than $10 apiece by mid-morning on Wednesday, equating to a market value north of $700 million.

The new Biohaven’s most advanced drug candidate is a medicine called troriluzole, which is in late-stage testing for obsessive compulsive disorder and a genetic condition known as spinocerebellar ataxia, or SCA. In the latter condition, however, Phase 3 clinical trial results released in May showed the drug did not perform significantly better than placebo on the study’s main measure. The drug has previously failed studies in Alzheimer’s disease and in severe anxiety.

Biohaven isn’t giving up on SCA yet, focusing on a subset of patients who might benefit and signaling plans to continue regulatory discussions. But it’s focusing more on another drug, dubbed BHV-7000 and acquired via a $100 million deal earlier this year. That medicine is in testing for epilepsy as well as mood and pain disorders.

The company also has a drug for spinal muscular atrophy in Phase 3 testing, a multiple myeloma treatment in a Phase 1 study and half a dozen other discovery-stage programs.

On October 5, 2022 AIGEN Sciences, an artificial intelligence (AI)-based new drug development company, reported that it had completed attracting 4.2 billion won in investment through pre-Series A (Press release, AIGEN Sciences, OCT 5, 2022, View Source [SID1234643559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Partners Investment, Blue Point Partners, Medytox Venture Investment, Quad Asset Management, and Korea University Technology Holdings participated in this investment.

Eisen Science will use this investment to advance artificial intelligence technology by expanding the virtual transcriptome map and to build an integrated platform including transcriptome/structure-based linked molecular design technology. In addition, the company plans to accelerate the development of its own anticancer drug and rare disease pipeline and recruit additional artificial intelligence, synthesis, and pharmacology/bio research personnel.

Eisen Science is an artificial intelligence (AI)-based new drug development company founded by Professor Jae-Woo Kang of Korea University in April last year. Eisen Science’s core new drug development artificial intelligence platform is an artificial intelligence technology based on transcriptome data, which can be used to screen and design drugs with new structures that induce transcriptome changes similar to knock down expression of disease targets. .

The company explained that transcriptome change-inducing drugs have the advantage of minimizing side effects caused by off-target effects of drugs, and can be applied to the development of treatments for intractable diseases for which the disease target is unknown by using the patient’s transcriptome information. am.

Jaewoo Kang, CEO of Eisen Science, said, "Through this investment, we plan to accelerate the development of our own new drug pipeline," adding, "We will develop lead substances in at least three pipelines by 2023 and create business development results with domestic and foreign pharmaceutical companies." "It is planned," he said.

Meanwhile, Igen Science has Vice President (CSO) Gwang-Ok Lee, who has been conducting research for 27 years at domestic pharmaceutical companies such as Hanmi Pharmaceutical, Bukwang Pharmaceutical, and Youngjin Pharmaceutical, and is in charge of planning, business development, and strategic partnerships for over 20 years at pharmaceutical companies such as SK Biopharmaceuticals, Chong Kun Dang, and Boryung. Vice President Kim Jong-ho (CBO) and others were recruited.